サポート ブログ Autoantibodies: Guardians or Aggressors?

Autoantibodies: Guardians or Aggressors?

Biointron 2024-01-26 Read time: 4 mins
Autoantibodies.jpg
Multiple pathways lead to autoantibody-induced pathology. DOI: 10.3389/fimmu.2017.00603

Autoantibodies, also known as natural autoantibodies, are antibodies that target the body's own proteins instead of foreign invaders like bacteria or viruses. In healthy individuals, autoantibodies are mostly IgM, which are encoded by unmutated V(D)J genes and show a moderate affinity and high avidity for self-antigens. They act as a first line of defense against infections, and likely play important roles in housekeeping functions and maintaining immune homeostasis. Meanwhile, pathogenic autoantibodies are commonly high-affinity, somatically mutated, class-switched IgGs. They can disrupt homeostatic pathways involved in cell clearance, antigen-receptor signaling, and cell effector functions.1

Normally, the immune system distinguishes between self and non-self-molecules, ensuring that it attacks only foreign substances. However, in autoimmune disorders, this recognition is affected. Examples include rheumatoid arthritis, lupus, and Hashimoto's thyroiditis. In these conditions, autoantibodies mistakenly target the body's tissues, causing inflammation, tissue damage, and a range of symptoms.

Detecting these autoantibodies has allowed for the use of disease-associated antigens in better diagnosis, prognosis and treatment. Their stability, for example, is typically much better than their related antigen. In addition, they have valuable potential in therapeutic use in vivo. Research has also shown that autoantibodies for certain diseases like systemic lupus may be detectable long before disease onset and function as biomarkers for therapeutic intervention.2

Systemic lupus erythematosus (SLE) is characterized by multiple organ inflammatory damage and a wide spectrum of autoantibodies. The anti-dsDNA and anti-Sm autoantibodies exhibit high specificity for SLE, contributing to the formation of immune complexes and inflammatory damage to the kidneys, skin, and central nervous system. Unfortunately, the exact mechanisms for autoantibodies in SLE are still unknown, and developing specific therapies against the pathogenic B cell subset and autoantibodies is a major hurdle.3

Besides SLE, recent studies have uncovered the role of autoantibodies in COVID-19. Using rapid extracellular antigen profiling, researchers found that patients with COVID-19 exhibited higher increases in autoantibody reactivities than uninfected individuals, as well as a high prevalence of autoantibodies against immunomodulatory proteins such as cytokines and chemokines. Furthermore, the autoantibodies disrupted immune function and virological control by affecting immunoreceptor signaling and peripheral immune cell composition. Therefore, further research in therapeutics should look at modulating these pathways and attenuating the autoantibodies.4

At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects. 


References

  1. Elkon, K., & Casali, P. (2008). Nature and functions of autoantibodies. Nature Clinical Practice. Rheumatology, 4(9), 491. https://doi.org/10.1038/ncprheum0895

  2. Ma, H., Murphy, C., & Loscher, C. E. (2022). Autoantibodies - enemies, and/or potential allies? Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.953726

  3. Lou, H., Ling, G. S., & Cao, X. (2022). Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target. Journal of Autoimmunity, 132, 102861. https://doi.org/10.1016/j.jaut.2022.102861

  4. Wang, E. Y., Mao, T., Klein, J., Dai, Y., Huck, J. D., Jaycox, J. R., Liu, F., Zhou, T., Israelow, B., Wong, P., Coppi, A., Lucas, C., Silva, J., Oh, J. E., Song, E., Perotti, E. S., Zheng, N. S., Fischer, S., Campbell, M., . . . Ring, A. M. (2021). Diverse functional autoantibodies in patients with COVID-19. Nature, 595(7866), 283-288. https://doi.org/10.1038/s41586-021-03631-y

Subscribe to our ブログ

Recent ブログ

The therapeutic efficacy of antibodies is closely related to their ability to recognize and bind specific epitopes on target antigens. Epitopes, or antigenic determinants, are a group of amino acids or other chemical groups that are part of a molecule to which an antibody attaches itself. Epitope characterization can help reveal the mechanism of antibody binding and apply intellectual property (patent) protection for novel antibodies, in addition to designing antibodies with high specificity and minimal cross-reactivity.

Jul 12, 2024
ブログ

Understanding the differences between antibody specificity and selectivity is essential for designing and interpreting antibody-based assays in research for experimental accuracy and data interpretation. Antibody specificity refers to an antibody's ability to recognize and bind to a particular epitope—a unique part of an antigen that elicits an immune response.

Jul 10, 2024
ブログ

Antibody-based assays are essential tools in biomedical research, providing the means to detect, quantify, and visualize specific proteins or antigens within complex biological samples. These assays' efficacy hinges on the antibodies' precise properties. While affinity, avidity, specificity, and selectivity are fundamental to antibody performance, the ultimate impact of these properties is heavily influenced by the experimental context in which the antibody is employed.

Jul 08, 2024
ブログ

Biologics, particularly antibodies, have become indispensable in biomedical research and therapeutic development. Research-use-only (RUO) biologics play a pivotal role in preclinical studies, providing researchers with the necessary tools to explore antibody functions and therapeutic potential in vivo.

Jul 04, 2024
ブログ

お客様の利便性を向上させるためにクッキーを使用しています。詳しくは プライバシーポリシー をご覧ください。